Recent reports dedicated to critical issues, opinions, and controversies in carotid artery stenosis [1] [2] [3] In the letter, 4 the authors describe how recent trials 5, 6 have not answered the most urgent question regarding the management of patients with SCS and ACS-a comparison of carotid endarterectomy (CEA), carotid artery stenting (CAS), and best medical therapy (BMT) for asymptomatic patients. Although several studies have tried to propose a solution to this dilemma, nobody has still solved this important issue.
Interim results from the Asymptomatic Carotid Surgery Trial 2 demonstrate that between February 2008 and September 2012 (55 months) the number of randomized patients was 986, recruiting on average about 18 patients per month. 7 At this rate, recruiters need another 223 months (18.5 years) to reach the goal of 5000 patients. Also, in this case, the results do not include a BMT arm analysis.
The Stent-Protected Angioplasty in Asymptomatic Carotid Artery Stenosis versus Endarterectomy (SPACE-2) study started in 2009 aiming to compare BMT with CEA and CAS in patients with severe asymptomatic carotid stenosis. 8 The aim of the study was to recruit about 3500 patients. Due to low recruitment, the trial committee decided in 2012 to change the protocol and to divide this 3-arm trial into 2 separate 2-arm clinical trials: CEA þ BMT versus BMT alone (SPACE-2A) and CAS þ BMT versus BMT alone (SPACE-2B). 9 The sample size for the overall trial was 3272 patients (SPACE-2A: 1636 and SPACE-2B: 1636). Unfortunately, it is beforehand terminated with no interim results for several reasons, including poor recruitment rate and financial factors. 10 A new analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial 2 (CREST-2) is currently recruiting participants with ACS having 70% stenosis, comparing either BMT alone versus BMT + CEA or BMT alone versus BMT + CAS. 11 Estimated primary completion date will be in December 2020.
No more trials are currently in progress regarding BMT versus CEA or CAS.
Although there are several calls to improve the management of ACS and to verify the effectiveness of invasive therapeutic maneuvers, the scientific community is responding slowly and always partially. Do we need a new trial BMT versus CEA/ CAS? The answer is certainly yes! But, do we really want to know the results? Probably, nowadays there is too much resistance to changing our thoughts about ACS, and ''unexpected'' results may be frightening, especially in European countries where CEA is performed in the majority of cases in patients with ACS. 12 
